Related references
Note: Only part of the references are listed.Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Hiroji Iwata et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
Mitch Dowsett et al.
CLINICAL CANCER RESEARCH (2015)
Which threshold for ER positivity? a retrospective study based on 9639 patients
M. Yi et al.
ANNALS OF ONCOLOGY (2014)
Evaluating the 21-gene assay Recurrence ScoreA® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer
Takayuki Ueno et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors
Jyothi S. Prabhu et al.
JOURNAL OF CANCER (2014)
Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype
Brenda Deyarmin et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
E. C. Inwald et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy
Ke-Da Yu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Takayuki Iwamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Breast Cancer Incidence Rates in U.S. Women Are No Longer Declining
Carol DeSantis et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissue-A New Option for Predictive Biomarker Assessment in Breast Cancer
Berit Maria Mueller et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2011)
Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer
Chungyeul Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
Frederick L. Baehner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Concordance Between Semiquantitative Immunohistochemical Assay and Oncotype DX RT-PCR Assay for Estrogen and Progesterone Receptors
Siobhan M. O'Connor et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2010)
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients
Sadako Akashi-Tanaka et al.
BREAST (2009)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
Sunil S. Badve et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic effect of estrogen receptor status across age in primary breast cancer
Niels Bentzon et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
